SCHEMBL15380386

SCHEMBL15380386

C#CC(C)(C)n1c2ccccc2c2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR3 P46089 1/20 0.43
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ POLB P06746 1/20 0.36
▸ KDM4E B2RXH2 3/20 0.35
▸ ATM Q13315 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ PER2 O15055 1/20 0.35
▸ CRY1 Q16526 1/20 0.35
▸ CRY2 Q49AN0 1/20 0.35
▸ LMNA P02545 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ KIF11 P52732 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ RCE1 Q9Y256 1/20 0.33
▸ ALKBH5 Q6P6C2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29625463 0.75 GPR3 (0.52) GPR3CYP1A2CYP2C19POLBKDM4E
SCHEMBL2608424 0.75 GPR3 (0.52) GPR3CYP1A2CYP2C19POLBKDM4E
SCHEMBL18381750 0.73 GPR3 (0.50) GPR3CYP1A2CYP2C19POLBKDM4E
SCHEMBL15836286 0.71 GPR3 (0.48) GPR3CYP1A2CYP2C19POLBKDM4E
SCHEMBL18995603 0.71 GPR3 (0.48) GPR3CYP1A2CYP2C19POLBKDM4E
SCHEMBL20691793 0.71 GPR3 (0.48) GPR3CYP1A2CYP2C19POLBKDM4E
SCHEMBL28023867 0.71 GPR3 (0.48) GPR3CYP1A2CYP2C19POLBKDM4E
SCHEMBL17827625 0.68 GPR3 (0.44) GPR3CYP1A2CYP2C19POLBKDM4E
SCHEMBL18595609 0.68 GPR3 (0.44) GPR3CYP1A2CYP2C19POLBKDM4E
SCHEMBL6468879 0.68 CYP1A2 (0.48) GPR3CYP1A2CYP2C19POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107674071-B Carbazole-containing sulfonamides as cryptochrome modulators 同步制药公司 2021-12-31 — — CN disclosed
US-10383880-B2 Carbazole-containing sulfonamides as cryptochrome modulators Synchronicity (US) 2019-08-20 — — US disclosed
US-10383880-B2 Carbazole-containing sulfonamides as cryptochrome modulators Synchronicity (US) 2019-08-20 — — US disclosed
EP-2855458-B1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS RESET THERAPEUTICS INC (US) 2018-08-08 — — EP disclosed
EP-2855458-B1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS RESET THERAPEUTICS INC (US) 2018-08-08 — — EP disclosed
US-20180071306-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2018-03-15 — — US disclosed
US-20180071306-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2018-03-15 — — US disclosed
US-20180071306-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2018-03-15 — — US disclosed
US-9775845-B2 Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2017-10-03 — — US disclosed
US-9775845-B2 Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2017-10-03 — — US disclosed
US-20160200732-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2016-07-14 — — US disclosed
US-20160200732-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS Synchronicity Pharma, Inc. 2016-07-14 — — US disclosed
US-9265772-B2 Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2016-02-23 — — US disclosed
US-9265772-B2 Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2016-02-23 — — US disclosed
US-9265772-B2 Carbazole-containing sulfonamides as cryptochrome modulators RESET THERAPEUTICS, INC. (US) 2016-02-23 — — US disclosed
EP-2855458-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS Reset Therapeutics, Inc. (US) 2015-04-08 — — EP disclosed
US-20130303524-A1 Carbazole-Containing Sulfonamides as Cryptochrome Modulators Synchronicity Pharma, Inc. 2013-11-14 — — US disclosed
WO-2013170186-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS RESET THERAPEUTICS, INC. (US) 2013-11-14 — — WO disclosed
US-20130303524-A1 Carbazole-Containing Sulfonamides as Cryptochrome Modulators Synchronicity Pharma, Inc. 2013-11-14 — — US disclosed
US-20130303524-A1 Carbazole-Containing Sulfonamides as Cryptochrome Modulators Synchronicity Pharma, Inc. 2013-11-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303524-A1 Carbazole-Containing Sulfonamides as Cryptochrome Modulators CRY1, CRY2, CRYAB GPR3 118/4885CYP1A2 174/4885CYP2C19 180/4885
US-20160200732-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS CRY1, CRY2, CRYAB GPR3 105/4885CYP1A2 165/4885CYP2C19 179/4885
US-10383880-B2 Carbazole-containing sulfonamides as cryptochrome modulators CRY1, CRY2, CRYAB GPR3 105/4885CYP1A2 165/4885CYP2C19 179/4885
US-20180071306-A1 CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS CRY1, CRY2, CRYAB GPR3 105/4885CYP1A2 165/4885CYP2C19 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback